
Opinion|Videos|December 17, 2024
Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer
Panelists discuss how emerging targeted therapies, including novel PI3K inhibitors and combination treatments, are advancing precision pathways in HR positive (HR+)/HER2 negative (HER2-) breast cancer, offering new hope for personalized treatment and improved patient outcomes.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
3
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
4
Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma
5





















































